In Vivo Cell Engineering Patents: Who Leads, Trends 2026
In Vivo Cell Engineering Patents: Mapping the Filers and the Gaps
51.6% of all 852 records sit with just five assignees, so freedom-to-operate work should start with those portfolios, not a broad search. Filings rose from 30 in 2017 to a peak of 96 in 2024, including a 55% increase between 2021 and 2024. 2025 and 2026 show fewer records only because publication has not caught up with filing, not because activity slowed.
- 1NOVARTIS AG171
- 2THE TRUSTEES OF THE UNIV OF PENNSYLVANIA99
- 3CAPSTAN THERAPEUTICS INC81
- 4ENLIVEX THERAPEUTICS RDO LTD56
- 5MEMORIAL SLOAN KETTERING CANCER CENT33
See the full in vivo cell engineering analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
What counts as in vivo cell engineering in this patent dataset?
This dataset covers filings that combine an in vivo delivery route, such as in vivo CAR constructs or targeted lipid nanoparticles, with claims addressing how the therapy behaves after dosing, including cell type selectivity, transient expression, dosing regimen and bystander transduction. It excludes filings that only describe ex vivo manufacturing without an in vivo functional claim. The search string used to build the dataset combines both sets of terms, so a record needs at least one from each side to appear.
Who holds the most patents in in vivo cell engineering?
The ranking lists 100 assignees by patent family count, with the leader holding 171 of the 852 records in scope, more than three times the tenth-place count of 27. The top five assignees combined hold 51.6% of all records, so a small number of organizations account for more than half the field. The rest of the ranking has a long tail of assignees with only a handful of filings each.
Is the in vivo cell engineering patent field still growing?
Yes, based on complete-year data: filings rose from 62 in 2021 to a peak of 96 in 2024, a 55% increase over that span. 2025 and 2026 figures in the raw data look lower, but that reflects the roughly 18-month lag between filing and publication rather than an actual slowdown. Any assessment of current-year activity should wait for those years to finish publishing before drawing conclusions.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on In Vivo Cell Engineering covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.